Fuji Pharma Co., Ltd.

Tokyo Stock Exchange 4554.T

Fuji Pharma Co., Ltd. Gross Profit for the year ending September 30, 2024: USD 124.14 M

Fuji Pharma Co., Ltd. Gross Profit is USD 124.14 M for the year ending September 30, 2024, a 12.33% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Fuji Pharma Co., Ltd. Gross Profit for the year ending September 30, 2023 was USD 110.52 M, a 9.90% change year over year.
Fuji Pharma Co., Ltd. Gross Profit for the year ending September 30, 2022 was USD 100.56 M, a -24.12% change year over year.
Fuji Pharma Co., Ltd. Gross Profit for the year ending September 30, 2021 was USD 132.52 M, a -6.03% change year over year.
Fuji Pharma Co., Ltd. Gross Profit for the year ending September 30, 2020 was USD 141.03 M, a -3.48% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

Tokyo Stock Exchange: 4554.T

Fuji Pharma Co., Ltd.

CEO	Mr. Toyoyuki Kamide
IPO Date	Feb. 22, 2010
Location	Japan
Headquarters	5-7 Sanban-cho
Employees	1,621
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Clinical Trials Cosmetics Drugstores & Retail Pharmacies Medical Instruments Personal Care

Description

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years